Mereo BioPharma Group (LTS:0A9G) Net Change in Cash : $-33.77 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mereo BioPharma Group Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Mereo BioPharma Group's Net Change in Cash for the three months ended in Dec. 2024 was $-10.68 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was $-33.77 Mil.

Mereo BioPharma Group Net Change in Cash Historical Data

The historical data trend for Mereo BioPharma Group's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Net Change in Cash Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Change in Cash

Get a 7-Day Free Trial

9.71

95.59

-59.22

-10.76

12.38

Mereo BioPharma Group Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Change in Cash	Get a 7-Day Free Trial															-5.11	-8.76	-8.01	-6.32	-10.68

Mereo BioPharma Group Net Change in Cash Calculation

Mereo BioPharma Group's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-32.834	+	-0.699	+	46.147	+	-0.233
	=	12.38

Mereo BioPharma Group's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -9.42 + 0 + 0 + -1.26

= -10.68

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mereo BioPharma Group Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Mereo BioPharma Group's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (LTS:0A9G) » Definitions » Net Change in Cash

Comparable Companies

LSE:OXB LSE:FARN LSE:IBT LSE:PRTC LSE:4BB LSE:AVCT LSE:BVXP LSE:HVO LSE:SCLP LSE:SBTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX

Traded in Other Exchanges

MREO:USA MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo BioPharma Group Headlines

No Headlines